Volume 16, Number 2—February 2010
Research
Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007
Eleni Galanis
, Laura MacDougall, Sarah Kidd, Mohammad Morshed, and the British Columbia Cryptococcus gattii Working Group
, Laura MacDougall, Sarah Kidd, Mohammad Morshed, and the British Columbia Cryptococcus gattii Working Group
Table 1
Characteristics of persons with cases of confirmed or probable Cryptococcus gattii infection, British Columbia, Canada, 1999–2007*
| Characteristic | Total | Confirmed | Probable | p value |
|---|---|---|---|---|
| No. cases | 218 | 124 | 94 | NA |
| Average incidence (million/year) | 5.8 | 3.3 | 2.5 | NA |
| No. cases in persons living on Vancouver Island |
161 (73.9) |
83 (66.9) |
78 (83.0) |
0.177 |
| Demographic data | ||||
| Male sex | 121 (55.5) | 73 (58.9) | 48 (51.1) | 0.440 |
| Age, y | ||||
| Mean | 58.7 | 58.7 | 58.7 | 0.988 |
| Range | 2–92 | 2–92 | 12–87 | NA |
| Children <18 y |
4 (1.8) |
3 (2.4) |
1 (1.1) |
0.463 |
| Clinical assessment | ||||
| Respiratory syndrome | 167 (76.6) | 85 (68.5) | 82 (87.2) | 0.031 |
| CNS syndrome | 17 (7.8) | 16 (12.9) | 1 (1.1) | 0.001 |
| Respiratory and CNS syndrome | 22 (10.1) | 20 (16.1) | 2 (2.1) | <0.001 |
| Other/unknown | 12 (5.5) | 3 (2.4) | 9 (9.6) | NA |
| Asymptomatic |
16 (7.3) |
6 (4.8) |
10 (11.0) |
0.120 |
| Hospitalized | 98 (60.9) | 58 (65.2) | 40 (55.6) | 0.434 |
| Immunocompromised | 70 (38.0) | 41 (38.7) | 29 (37.2) | 0.870 |
*Frequencies were calculated by using persons from whom information was available, which varied for each question or data point. All values given as no. (%) persons except as indicated. NA, not available; CNS, central nervous system.
1Members involved in this study were Patrick Doyle, John Galbraith, Linda Hoang, Pamela Kibsey, Min-Kuang Lee, Sultana Mithani, Marc Romney, and Diane Roscoe.
Page created: August 29, 2012
Page updated: August 29, 2012
Page reviewed: August 29, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.